Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry

References

• Ostan R, Monti D, Gueresi P, et al. Gender, aging and longevity in humans: an update of an intriguing/neglected scenario paving the way to a gender-specific medicine. Clinical Science. 2016;130:1711–1725.
   PubMed Web of Science ®Google Scholar
• AIHW. Ageing and the health system: challenges, opportunities and adaptations. Australian Institute of Health and Welfare 2014 Australia’s health 2014. 2014;Australia’s health series no. 14. (Cat. no. AUS 178. Canberra: AIHW.).
   Google Scholar
• Faulkner D, Feist HB, Lewis J. Ageing research in Australia: reflecting on Graeme Hugo’s four decades of contribution. Australian Geographer. 2016;47:399–415.
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Karapetis CS, Ullah S, et al. Survival improvements associated with access to biological agents: results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta Oncologica. 2016;55:480–485.
   PubMed Web of Science ®Google Scholar
• Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. JCO. 2005;23:3112–3124.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. JCO. 2003;21:1383–1389.
   PubMed Web of Science ®Google Scholar
• Bernardi D, Errante D, Tirelli U, et al. Insight into the treatment of cancer in older patients: developments in the last decade. Cancer Treat Rev. 2006;32:277–288.
   PubMed Web of Science ®Google Scholar
• Faivre J, Lemmens VE, Quipourt V, et al. Management and survival of colorectal cancer in the elderly in population-based studies. Europ J Cancer (Oxford, England: 1990). 2007;43:2279–2284.
   PubMed Web of Science ®Google Scholar
• Neo EL, Beeke C, Price T, et al. South Australian clinical registry for metastatic colorectal cancer. ANZ J Surg. 2011;81:352–357.
   PubMed Web of Science ®Google Scholar
• Shenoy P, Harugeri A. Elderly patients' participation in clinical trials. Perspect Clin Res. 2015;6:184–189.
   PubMedGoogle Scholar
• Yap R, Oliva K, Wilkins S, et al. Colorectal cancer surgery in the very elderly: nonagenarians. Dis Colon Rectum. 2016;59:501–507.
   PubMedGoogle Scholar
• Arenal JJ, Tinoco C, Labarga F, et al. Colorectal cancer in nonagenarians. Colorectal Dis.2012;14:44–47.
   PubMedGoogle Scholar
• Biondi A, Vacante M, Ambrosino I, et al. Role of surgery for colorectal cancer in the elderly. WJGS. 2016;8:606–613.
   Web of Science ®Google Scholar
• Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663–666.
   PubMed Web of Science ®Google Scholar
• Patel SS, Nelson R, Sanchez J, et al. Elderly patients with colon cancer have unique tumor characteristics and poor survival. Cancer. 2013;119:739–747.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Poorman K, Arguello D et al. Impact of patient age on molecular alterations in left-sided colorectal tumors. J Clin Oncol. 2017;35 (suppl; abstr 3592). 2017 ASCO Annual Meeting.
   Web of Science ®Google Scholar
• Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224–237.
   PubMedGoogle Scholar
• Formiga F, Ferrer A, Chivite D, et al. Predictors of long-term survival in nonagenarians: the NonaSantfeliu study. Age Ageing. 2011;40:111–116.
   PubMed Web of Science ®Google Scholar
• Patnaik JL, Byers T, DiGuiseppi C, et al. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst. 2011;103:1101–1111.
   PubMedGoogle Scholar
• Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). JCO. 2014;32:LBA3–LLBA.
   Web of Science ®Google Scholar
• Ciombor KK, Bekaii-Saab T. A comprehensive review of sequencing and combination strategies of targeted agents in metastatic colorectal cancer. Oncologist. 2018;23:25–34.
   PubMed Web of Science ®Google Scholar
• Merlin F, Prochilo T, Tondulli L, et al. Colorectal cancer treatment in elderly patients: an update on recent clinical studies. Clin Colorectal Cancer. 2008;7:357–363.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. JCO. 2006;24:4085–4091.
   PubMed Web of Science ®Google Scholar
• Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer. 2006;94:969–975.
   PubMed Web of Science ®Google Scholar
• Khattak MA, Townsend AR, Beeke C, et al. Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. Europ J Cancer (Oxford, England: 1990). 2012;48:1293–1298.
   PubMed Web of Science ®Google Scholar
• Yu J, Reddy NM, Rajput A, et al. Outcomes and toxicities among octogenarians and nonagenarians with colorectal cancer (crc) treated with chemotherapy or concurrent chemoradiation - a single institution study. J Clin Oncol. 2006;24:13514.
   Google Scholar
• Reddy N, Yu J, Fakih MG. Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. Clin Colorectal Cancer. 2007;6:362–366.
   PubMed Web of Science ®Google Scholar
• Rivoirard R, Chargari C, Kullab S, et al. Chemotherapy Regimen in Nonagenarian Cancer Patients: A Bi-Institutional Experience. Chemotherapy. 2016;61:65–71.
   PubMed Web of Science ®Google Scholar